Primary care physicians are uniquely placed to offer holistic, patient-centred care to patients with T2DM. While the recent FDA-mandated cardiovascular outcome trials offer a wealth of data to inform treatment discussions, they have also contributed to increasing complexity in treatment decisions, and in the guidelines that seek to assist in making these decisions. To assist physicians in avoiding treatment inertia, Primary Care Diabetes Europe has formulated a position statement that summarises our current understanding of the available T2DM treatment options in various patient populations. New data from recent outcomes trials is contextualised and summarised for the primary care physician. This consensus paper also proposes a unique and simple tool to stratify patients into 'very high' and 'high' cardiovascular risk categories and outlines treatment recommendations for patients with atherosclerotic cardiovascular disease, heart failure and chronic kidney disease. Special consideration is given to elderly/frail patients and those with obesity. A visual patient assessment tool is provided, and a comprehensive set of prescribing tips is presented for all available classes of glucose-lowering therapies. This position statement will complement the already available, often specialist-focused, T2DM treatment guidelines and provide greater direction in how the wealth of outcome trial data can be applied to everyday practice., Competing Interests: Declaration of Competing Interest XC has received consultancy and speaker fees from Abbott Laboratories, AstraZeneca, Boehringer Ingelheim, Eli Lilly, Merck Sharp & Dohme, Novartis, Novo Nordisk, Roche and Sanofi; and grant funding from AstraZeneca, Boehringer Ingelheim, Novartis and Sanofi. SS has received consultancy and speaker fees from Amgen, Boehringer Ingelheim, Napp Pharmaceuticals, Novartis and Roche; advisory board, consultancy and speaker fees from AstraZeneca, Eli Lilly, Merck Sharp & Dohme, Novo Nordisk and Sanofi; and trial grant funding from AstraZeneca, Janssen Pharmaceutica, Sanofi and Servier Laboratories. SB has received advisory board and speaker fees from AstraZeneca, Bayer, Boehringer Ingelheim, Janssen Pharmaceutica and Novo Nordisk; advisory board fees from Abbott Laboratories, Merck Sharp & Dohme, Sanofi and Xeris Pharmaceuticals; and speaker fees from Eli Lilly. SBH has received advisory board and consultancy fees from Abbott Laboratories, AstraZeneca, Boehringer Ingelheim, Eli Lilly, Janssen Pharmaceutica, Merck, Novo Nordisk and Sanofi. SJ received speaker fees from AstraZeneca, Boehringer Ingelheim, Eli Lilly, Novo Nordisk and Sanofi. MM-C has received fees from AstraZeneca, Bayer, Boehringer Ingelheim, Eli Lilly, GlaxoSmithKline, Merck Sharp & Dohme, Novartis, Novo Nordisk and Sanofi; and grant funding from AstraZeneca, Eli Lilly, GlaxoSmithKline, Merck Sharp & Dohme and Sanofi. AMJN has received speaker fees from Becton Dickinson; and advisory board feed from Sanofi. PT has received advisory board, consultancy and speaker fees from Eli Lilly; advisory board and consultancy fees from Boehringer Ingelheim and advisory board fees from Novo Nordisk. KK has received advisory board, consultancy and speaker fees from Novo Nordisk and Sanofi; consultancy and speaker fees from Berlin Chemie, Boehringer Ingelheim, Novartis, Novo Nordisk, Roche, Sanofi and Servier Laboratories; and grant funding from AstraZeneca, Boehringer Ingelheim, Eli Lilly, Merck Sharp & Dohme, Novartis, Novo Nordisk, Pfizer, Sanofi and Servier Laboratories., (Copyright © 2020. Published by Elsevier B.V.)